Get the Stockscreener App
0.9182
1.02%
-0.0095
After Hours:
.95
0.0318
+3.46%
Werewolf Therapeutics Inc stock is traded at $0.9182, with a volume of 723.11K.
It is down -1.02% in the last 24 hours and down -45.02% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$0.9277
Open:
$0.91
24h Volume:
723.11K
Relative Volume:
0.90
Market Cap:
$41.99M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-0.8829
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
-20.16%
1M Performance:
-45.02%
6M Performance:
-7.25%
1Y Performance:
-52.42%
1-Day Range:
$0.89
$0.9653
1-Week Range:
$0.89
$1.21
52-Week Range:
$0.595
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.9182 | 45.03M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Werewolf Therapeutics Inc. stock trend forecastMarket Activity Summary & Daily Technical Stock Forecast Reports - newser.com
How Werewolf Therapeutics Inc. stock performs after earningsSwing Trade & Daily Price Action Insights - newser.com
Why Werewolf Therapeutics Inc. stock is rated strong buyMarket Sentiment Report & Trade Opportunity Analysis Reports - Fundação Cultural do Pará
Werewolf Therapeutics Inc. stock trendline breakdown2025 Price Momentum & Consistent Income Trade Ideas - newser.com
What MACD signals say about Werewolf Therapeutics Inc.2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Will Werewolf Therapeutics Inc. price bounce be sustainableJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - newser.com
Will Werewolf Therapeutics Inc. stock recover faster than marketFed Meeting & Low Drawdown Trading Techniques - newser.com
Advanced analytics toolkit walkthrough for Werewolf Therapeutics Inc.Market Growth Summary & Precise Swing Trade Alerts - newser.com
Evnin Luke, director at Werewolf Therapeutics, sells $154k in HOWL By Investing.com - Investing.com South Africa
Werewolf Therapeutics (HOWL) 10% owners sell $241k in stock By Investing.com - Investing.com Nigeria
Evnin Luke, director at Werewolf Therapeutics, sells $154k in HOWL - Investing.com Nigeria
Mpm Bioventures sells Werewolf Therapeutics (HOWL) shares for $241k By Investing.com - Investing.com Nigeria
Mpm Bioventures sells Werewolf Therapeutics (HOWL) shares for $241k - Investing.com India
Werewolf Therapeutics (HOWL) 10% owners sell $241k in stock - Investing.com
Analyzing recovery setups for Werewolf Therapeutics Inc. investorsPortfolio Profit Report & Stock Market Timing Techniques - newser.com
Citizens reiterates Market Outperform rating on Werewolf Therapeutics stock By Investing.com - Investing.com Nigeria
Visual trend scoring systems applied to Werewolf Therapeutics Inc.Market Risk Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Citizens reiterates Market Outperform rating on Werewolf Therapeutics stock - Investing.com
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $8.00 Consensus Price Target from Brokerages - Defense World
Werewolf Therapeutics Inc (HOWL) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Is Werewolf Therapeutics Inc. stock bottoming outWeekly Trade Review & Verified Chart Pattern Trade Signals - newser.com
Will Werewolf Therapeutics Inc. stock reach all time highs in 2025Trade Signal Summary & Technical Pattern Alert System - newser.com
FY2025 Earnings Estimate for HOWL Issued By Leerink Partnrs - Defense World
Wedbush Expects Increased Earnings for Werewolf Therapeutics - Defense World
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for ... - Bluefield Daily Telegraph
Werewolf (Nasdaq: HOWL) unveils masked T cell engager, shows tumor-selective WTX-124 - Stock Titan
Mpm Bioventures sells Werewolf Therapeutics (HOWL) stock for $295k By Investing.com - Investing.com South Africa
Werewolf Therapeutics: Multiple 10% owners sell $295k in shares By Investing.com - Investing.com Philippines
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):